Sierra Oncology Inc (NASDAQ:SRRA) shares were up 6.6% during mid-day trading on Tuesday . The company traded as high as $3.15 and last traded at $3.09. Approximately 642,516 shares were traded during trading, an increase of 76% from the average daily volume of 365,398 shares. The stock had previously closed at $2.90.

SRRA has been the topic of several analyst reports. Jefferies Group upgraded Sierra Oncology from a “hold” rating to a “buy” rating in a research note on Monday, October 23rd. Zacks Investment Research upgraded Sierra Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, November 14th. Finally, ValuEngine upgraded Sierra Oncology from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $4.00.

Sierra Oncology (NASDAQ:SRRA) last posted its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.03. sell-side analysts forecast that Sierra Oncology Inc will post -0.85 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at

About Sierra Oncology

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with's FREE daily email newsletter.